14 November 2017
MSD Animal Health to Acquire Vilsan Pharmaceuticals
Expands Product Portfolio in Turkey
ISTANBUL, TURKEY, November 14, 2017 – MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, today announced it has signed an agreement to acquire Vilsan Pharmaceuticals, a division of Vimar Group, based in Turkey. Vilsan Pharmaceuticals is the largest privately-held producer of animal health products in Turkey, with an extensive portfolio of pharmaceutical products, notably for ruminants and a manufacturing facility.
“We are excited about the opportunity to expand and complement our MSD Animal Health portfolio with products from Vilsan Pharmaceuticals, which will bring value and new options to our customers in this growing region,” said Philippe Houffschmitt, General Manager, MSD Animal Health Turkey.
The agriculture industry is an important driver of the economy in Turkey, the second most populous country in Europe. Turkey is experiencing robust growth in the value of animal production, driven by the increased demand for protein.
“We are very pleased to join with MSD Animal Health to build upon our 30-year commitment to advance the health of animals,” said Burhan Haci, CEO of Vilsan Pharmaceuticals. “Their expertise, commercial reach and worldwide network, combined with our portfolio and production capacity, represents a tremendous opportunity to serve producers and veterinarians in this region.”
The terms of the agreement were not disclosed. This agreement is subject to regulatory review and certain closing conditions, and is expected to close in the coming months.
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).